TABLE 1.
Target volume coverage and doses to OAR
| Synergy | Halcyon | p | |
|---|---|---|---|
| PTVBoost | |||
| D98% (Gy) | 57.8 ± 0.4 | 58.4 ± 0.4 | 0.001 |
| D02% (Gy) | 61.7 ± 0.4 | 61.2 ± 0.3 | <0.001 |
| D95% (Gy) | 58.3 ± 0.4 | 58.8 ± 0.3 | 0.001 |
| DMean (Gy) | 60.2 ± 0.3 | 60.0 ± 0.2 | NS |
| HI | 0.07 ± 0.01 | 0.05 ± 0.01 | <0.001 |
| CI | 1.17 ± 0.05 | 1.26 ± 0.10 | <0.001 |
| PTV (without PTVBoost) | |||
| D98% (Gy) | 49.4 ± 0.5 | 49.4 ± 0.4 | NS |
| D02% (Gy) | 58.3 ± 0.4 | 58.9 ± 0.7 | 0.002 |
| D95% (Gy) | 50.1 ± 0.4 | 50.5 ± 0.3 | 0.004 |
| DMean (Gy) | 53.8 ± 0.3 | 54.4 ± 0.7 | 0.001 |
| HI | 0.16 ± 0.01 | 0.18 ± 0.01 | 0.018 |
| CI | 1.13 ± 0.02 | 1.10 ± 0.03 | <0.001* |
| Rectum | |||
| DMean (Gy) | 17.4 ± 4.0 | 18.0 ± 4.5 | NS |
| Bladder | |||
| DMean (Gy) | 16.2 ± 6.3 | 16.1 ± 6.1 | NS |
| Femoral Head left | |||
| DMean (Gy) | 10.6 ± 2.9 | 13.6 ± 2.7 | 0.002 |
| Femoral Head right | |||
| DMean (Gy) | 10.3 ± 2.6 | 13.7 ± 3.3 | 0.002 |
| Penile Bulb | |||
| DMean (Gy) | 22.7 ± 12.2 | 25.2 ± 12.1 | 0.038 |
Target volume coverage and dose to organs at risk in Synergy Agility and Halcyon plans. Stated values indicate mean ± standard deviation. Statistical significance was defined as a two‐sided p < 0.05. Statistical significance was tested by matched‐pairs t‐tests in case of normally distributed parameters. In case of non‐normally distributed parameters, Wilcoxon matched‐pairs signed‐rank tests (*) were applied instead. OAR, Organ at risk; HI, Homogeneity Index; CI, Conformity Index; NS, Not significant.